WO2004045612A8 - Use of a proton pump inhibitor for preventing postoperative nausea and vomiting - Google Patents

Use of a proton pump inhibitor for preventing postoperative nausea and vomiting

Info

Publication number
WO2004045612A8
WO2004045612A8 PCT/SE2003/001774 SE0301774W WO2004045612A8 WO 2004045612 A8 WO2004045612 A8 WO 2004045612A8 SE 0301774 W SE0301774 W SE 0301774W WO 2004045612 A8 WO2004045612 A8 WO 2004045612A8
Authority
WO
WIPO (PCT)
Prior art keywords
vomiting
proton pump
pump inhibitor
preventing postoperative
postoperative nausea
Prior art date
Application number
PCT/SE2003/001774
Other languages
French (fr)
Other versions
WO2004045612A1 (en
Inventor
Ulrich Thissen
Original Assignee
Astrazeneca Ab
Ulrich Thissen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Ulrich Thissen filed Critical Astrazeneca Ab
Priority to AU2003279667A priority Critical patent/AU2003279667A1/en
Publication of WO2004045612A1 publication Critical patent/WO2004045612A1/en
Publication of WO2004045612A8 publication Critical patent/WO2004045612A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Abstract

A method for preventing postoperative nausea and vomiting in patients following anaesthesia by prophylaxis and/or treatment with a proton pump inhibitor compound. The proton pump inhibitor compound may be administered alone and/or in combination with other drugs, such as an 5-HT3 receptor antagonist and/or a corticosteriod. The method is also applicable more in general in patients on high risk of nausea and vomiting.
PCT/SE2003/001774 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting WO2004045612A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003279667A AU2003279667A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203410-6 2002-11-18
SE0203410A SE0203410D0 (en) 2002-11-18 2002-11-18 New use

Publications (2)

Publication Number Publication Date
WO2004045612A1 WO2004045612A1 (en) 2004-06-03
WO2004045612A8 true WO2004045612A8 (en) 2005-03-17

Family

ID=20289602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/001774 WO2004045612A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting

Country Status (3)

Country Link
AU (1) AU2003279667A1 (en)
SE (1) SE0203410D0 (en)
WO (1) WO2004045612A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007131070A2 (en) * 2006-05-04 2007-11-15 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
PL3354276T3 (en) 2007-11-13 2020-09-21 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist

Also Published As

Publication number Publication date
AU2003279667A1 (en) 2004-06-15
SE0203410D0 (en) 2002-11-18
WO2004045612A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
MX2007006063A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury.
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2006058007A3 (en) Jnk inhibitors for treatment of cns injury
TW200505881A (en) Tri(cyclo) substituted amide compounds
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
WO2004062624A3 (en) Method of treating nausea, vomiting, retching or any combination thereof
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
MY146794A (en) Use of an alpha-2-delta ligand for the treatment of luts
TW200621785A (en) Analgesic
WO2004045612A8 (en) Use of a proton pump inhibitor for preventing postoperative nausea and vomiting
CA2540102A1 (en) A combination of candesartan and rosuvastatin for the treatment of atherosclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 23/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP